Table 1.
Summary of HAEC pathway analysis.
| MicroRNA | II. Top canonical pathways in HAECs | P value | DIANA or IPA-predicted pathway targets repressed ≥ 1.5-fold in HAECs & differentially expressed in PBMCs | III. Top molecular and cellular functions and physiological systems in HAECs | P value | DIANA or IPA-predicted pathway targets repressed ≥ 1.5-fold in HAECs & differentially expressed in PBMCs |
|---|---|---|---|---|---|---|
| miR-103a-2-5p | EIF2 signaling | 1.4 × 10−10 | N/A | Cell death and survival | 1.6 × 10−3–4.3 × 10–22 | ATF6, BMI1, BNIP3L, HIF1A, HSPA5, LMO4, PARP1, PTPN11, RAD21, RAD23B, TFRC |
| Protein ubiquitination | 3.2 × 10–8 | HSPA5 | Cell cycle | 1.8 × 10−3–1.1 × 10–20 | BMI1, HIF1A, RAD21, TFRC | |
| Interferon signaling | 4.5 × 10−8 | N/A | Cellular assembly and organization | 1.5 × 10−3–1.1 × 10−20 | PARP1, RAD21 | |
| Mitotic roles of polo-like kinase | 7.9 × 10−8 | RAD21 | DNA replication, recombination, and repair | 1.6 × 10−3–1.1 × 10−20 | BMI1, PARP1, RAD23B, PARP1 | |
| Cell cycle control of chromosomal replication | 1.6 × 10–7 | N/A | Cellular growth and proliferation | 1.8 × 10−3–9.1 × 10−19 | ACAT1, AMD1, BMI1, HIF1A, HSPA5, PARP1, PROS1, RAD21, TFRC, TPN11 | |
| Cardiovascular system development and function | 1.3 × 10−3–4.1 × 10–7 | HSPA5, PROS1 | ||||
| miR-585-5p | EIF2 signaling | 2.3 × 10–15 | N/A | Cell death and survival | 6.9 × 10−4–2.1 × 10–22 | PARP1 |
| Mitotic roles of polo-like kinase | 6.6 × 10–9 | N/A | Cell cycle | 7.7 × 10−4–5.2 × 10–21 | N/A | |
| Cell cycle control of chromosomal replication | 9.2 × 10–9 | N/A | Cellular assembly and organization | 7.6 × 10−4–1.1 × 10−19 | PARP1 | |
| Regulation of eIF4 and p70S6K signaling | 3.3 × 10–8 | N/A | DNA replication, recombination, and repair | 5.4 × 10−4–1.1 × 10−19 | PARP1 | |
| mTOR signaling | 7.5 × 10–8 | N/A | Cellular growth and proliferation | 5.3 × 10−4–9.1 × 10−17 | N/A | |
| Cardiovascular system development and function | 6.8 × 10−4–1.2 × 10–10 | PARP1 |